Chief Executive Officer
Erez Aminov is an experienced biotechnology consultant and investor. He is the CEO of Mira Pharmaceuticals (NASDAQ) and the founder of Locate Venture Corp. Additionally, Erez is a consultant for Telomir Pharmaceuticals, where he utilizes his vast knowledge and experience to drive growth and success.
Erez’s accomplishments include identifying potential partnerships with major pharmaceutical and medical research centers and a deep understanding of early-stage startup growth and vertical integration. His vast industry network, which includes investment banks, PR and IR firms, and pharmaceutical contract development and manufacturing, has proven invaluable in driving startup success.
Erez holds a B.A. in Accounting from Touro University in New York. He also served as a MyMD Pharmaceuticals (NASDAQ) senior consultant, providing valuable insights and guidance to support the company’s growth and success.
Outside of work, Erez is a dedicated family man and avid traveler. He loves exploring new cultures and cuisines and believes in giving back to his community through various philanthropic efforts.
Christos Nicholoudis, Esq.
Christos Nicholoudis joined the board of MIRA Pharmaceuticals in March 2023 as General Counsel for the company. A former public defender for the 12th Judicial Circuit for the State of Florida from 2019 to 2022, Mr. Nicholoudis developed invaluable courtroom and trial experience. He has represented clients struggling with substance abuse and his firsthand knowledge of the devastating effects of addiction provides Mira with a unique perspective and deep commitment to its mission. After his employment with the State, Mr. Nicholoudis started his own practice in February 2022, where he handles a wide range of legal matters including contract work, personal injury, real estate, wills trusts and estates and criminal law. Prior to his legal career, Mr. Nicholoudis worked in the hospitality industry where he owned and operated a restaurant in Bradenton Florida from 2012 to 2020 while simultaneously working to develop a 5-star hotel in Mykonos Greece with his family.
Mr. Nicholoudis is a 2012 graduate of Cornell University’s School of Hotel Administration where he received a B.S. in hospitality and a 2017 graduate of Stetson College of Law where he received his J.D. He is admitted to the bar in New York, Florida, Texas, and Washington D.C. He speaks English, Greek, Russian and Hebrew and has exceptional public speaking skills. Aside from his scholastic achievements, Mr. Nicholoudis has been an athlete for his entire life. He graduated in 2008 from the IMG sports academy where he spent 10 years playing tennis, ice hockey and golf while also studying music and theater. He is a classically trained tenor who continues to volunteer in local community theater.
Chris Chapman, MD
Chris Chapman, M.D. serves as an appointed a director for MIRA1a Therapeutics Inc. Prior to joining MIRA1a, and since 2015, Dr. Chapman serves as the current President, Chief Medical Officer and Director of MyMD Pharmaceuticals, Inc., and since 1999, Dr. Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. In addition, from 2003-2004, Dr. Chapman served as the Associate Director of Drug Safety, Pharmacovigilance, and Clinical Operations for Organon Pharmaceuticals, where he was responsible for the supervision of four fellow M.D.s and 10 drug safety specialists.
Prior to his time at Organon, Dr. Chapman served as Director, Medical Affairs, Drug Safety and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995-2003, where he grew the division from no employees to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers and supporting staff. Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.) from 2007-2016, including as a member of the Audit Committee from 2007-2014, chairperson of the Compensation Committee from 2007-2014, and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert, and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects.
Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and tuberculosis, which was organized in 2006. Dr. Chapman is a graduate of the Harvard Kennedy School of Cambridge, Massachusetts for financial management in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown. Prior to his time at Georgetown, Dr. Chapman served in the air force as a B-52 crew chief in the Vietnam era.
Director and Chair of Audit Committee
Mr. Daly currently serves as Managing Partner at Dalglish Investment Holdings, LLC, an advisor and provider of seed capital to startup companies. Before establishing Dalglish, Mr. Daly worked on Wall Street for over 30 years. He began his career with Smith Barney H.U. in 1985, before joining the Asset management Group at Solomon Brothers in 1988. In 1994, he became a member of the Investment Banking Division of Paine Webber with a focus on Convertible Structured Products. He joined Omicron Capital, a private Equity Fund, in 1997 as the CFO. In 2006, Mr. Daly was a founding partner of Rockmore Capital, where he served as the CFO and member of the Investment Committee. Mr. Daly is a graduate of Fordham University and received his MBA from Columbia University.
Hugh McColl III
Hugh currently serves as a Partner at Collwick Capital, a boutique alternative investment firm. Before founding Collwick Capital, he spent 14 years in the hedge fund industry. Hugh was a private investments portfolio manager for Round Table Investment Management and McColl Brothers Lockwood, served as the COO for M&M Partners and was the CEO and Portfolio Manager for McColl Partners. From 1991 to 1996, Hugh served as the President of The Shelton Companies.
Hugh is a graduate of the University of North Carolina and received an MBA from the University of Virginia Darden School of Business. He currently serves on the Board of Directors of Fintag Holdings, Inc. and of Heritage Brands, Inc. and is a Senior Advisor to Brown Brothers Harriman’s Capital Partners Group.
Talhia Tuck, JD
Talhia Therese Tuck is currently serving as the Program Project Director of Georgetown Law School’s Innovative Policing Program since November 2019 as its first Program Associate. Prior to holding this position, she was an Associate Director of Admissions at Georgetown University for four years, where she evaluated applications for the undergraduate schools; served as the admissions representative for multiple regions; and chaired several admissions committees. In this role, she also served on numerous educational panels and conducted outreach in the Washington, D.C. area.
Before joining the Georgetown University community, Talhia worked in the investment relations and communications field, where she served as Vice President for Communications and Investor Relations at a healthcare company. In this capacity, she was responsible for coordinating communications with shareholders, the financial community, and the media. In addition to her communications experience, Talhia also has experience working in the legal field. Following her graduation from law school, she participated in the Ropes & Gray New Alternatives Program as a Fellow at the Office of the State’s Attorney for Montgomery County, Maryland. Subsequently, she worked in the Corporate Department at Ropes & Gray in Washington, DC.
Prior to attending law school, Talhia was a journalist with MSNBC, NBC News, ABC News, and the CBS affiliate, WINK-TV. She also worked as an admissions officer for Harvard College at Harvard University. Immediately after graduating from college, Talhia worked as a financial analyst at Goldman Sachs in the Investment Management Division. Talhia received her A.B. from Harvard College, cum laude, and received her J.D. from Harvard Law School.
Brad Kroenig is a fashion-industry icon, celebrity influencer, and accomplished investor. His global and high-powered network includes influential leaders in the arts, politics, and business, including Wall Street CEOs, analysts, and economists. He has helped start-ups become successful publicly-traded companies, including in the pharmaceutical industry. Vogue ranked him the #3 best male model of all time. He has been the face of Chanel, Fendi, Ralph Lauren, and many other top fashion labels. He brings unique insights and an unparalleled global perspective to MIRA1a’s board.
Mr. Jerman, age 57, has served as the managing partner at Hollywell Partners, a professional accounting and finance consulting firm, since May 2019, and has provided chief financial officer and other services to multiple private equity-backed companies in the energy, SaaS, and manufacturing industries. Prior to his role with Hollywell Partners, he was a Director with PwC in the US and UK from January 2007 to August of 2019 and was a Captain with the United States Air Force from July 2003 to June 2015. He has led global public and private client engagements in the industries of retail and consumer, energy, utilities and mining, and transportation and logistics. Mr. Jerman has significant experience in client equity and debt offerings, business combinations inclusive of public listing and reporting requirements, initial valuations and ongoing goodwill impairment analyses, share-based awards, restructuring, and global taxes, as well as stakeholder management, specifically with board and management presentation experience to include annual and quarterly requirements, fee negotiations, technical accounting and finance discussions, and fraud and non-compliance investigations. Mr. Jerman has specialized in rapid project mobilization and deployment of skilled resources for emergency issues, design, and implementation of small to large scale assurance requirements and advisory projects. Mr. Jerman’s additional experience includes leading PwC’s data acquisition methods and tools, client acquisitions and systems implementations to include new SOX-compliant control plan implementations across multiple systems, leading co-sourced internal audit projects, and time spent driving PwC’s lean efficiency initiatives. Mr. Jerman was a member of the PwC national office within the SEC PCAOB quality group supporting Europe and the EMEA regions with complex accounting and audit consultations. Mr. Jerman also serves as a member of the board of directors of Inhibitor Therapeutics, Inc. (OTC:INTI). He earned a B.S. in accounting from the University of South Florida, an M.S. in accounting from the University of Tampa, and an M.B.A. from the University of Oxford.